Multi-tenant SaaS Regulatory Information Management application from ArisGlobal, targeted at global pharma, biotech, medical device, and CRO regulatory affairs teams. Interoperates with LifeSphere Safety and includes an embedded GenAI/agentic AI layer (NavaX).
LifeSphere Regulatory is a suite of eight named modules: RIM (planning, tracking, registration management), Product Compliance (IDMP/xEVMPD), Documents (content repository), Submissions (compile/publish), Labeling, Analytics, Health Authority Interactions (NavaX-powered), and Regulatory Intelligence (NavaX-powered). A separate purpose-built variant, Investigational Product RIMS, launched February 2023 for emerging-stage life sciences and medical device companies, is marketed as a "pre-validated, turnkey solution."
ArisGlobal is a privately-held life sciences software vendor headquartered in Miami, Florida (Nordic Capital acquired in 2019 at ~USD 700M valuation). The Regulatory footprint expanded with two 2023 acquisitions — Amplexor Life Sciences (publishing, labeling, QMS) and SPORIFY (EMA SPOR/IDMP master data). In July 2024 the suite was relaunched with embedded NavaX GenAI capabilities and "50%+ efficiency gains." At Breakthrough 2025 ArisGlobal introduced LifeSphere Unify (cross-domain orchestration), NavaX Insights (analytics), and NavaX Agents (agentic AI).
LifeSphere Regulatory is "trusted by over 30 leading life science organizations" — a markedly smaller installed base than the LifeSphere Safety platform.
Pharmaceutical Edition
Investigational Product RIMS — a pre-validated, turnkey solution announced February 2023 for emerging-stage life sciences and medical device companies, focusing on prioritized functionality for early-pipeline portfolios.
Core Capabilities
Multi-tenant SaaS. ArisGlobal describes the platform as "a flexible and scalable SaaS approach." Nordic Capital's 2019 announcement confirms the transition from on-premise to SaaS. The public cloud provider (AWS, Azure, or GCP) is undisclosed. ArisGlobal markets "seamless integration capabilities" through an open architecture; the specific REST/webhook/connector inventory is undisclosed. Data residency commitments are not stated on RIM pages, despite regional offices in Europe, India, Japan, and China. Standards support: eCTD (versions not enumerated), IDMP/SPOR (via Product Compliance and SPORIFY). xEVMPD and HL7-FHIR support are reported by third-party analysis rather than stated on the vendor's current RIM page. SSO and named connectors (Veeva, SAP, Documentum) are undisclosed.
No list or tier pricing is published; pricing is enterprise-only and fully gated. Subscription SaaS, reportedly billed per-user or per-module, unconfirmed by the vendor. Demos are offered via a "Book a Demo" form; no public free trial exists. Deal sizes and minimum commitments are undisclosed. The April 2025 "Shared Success Model" is described as a value-first engagement commitment that guarantees automation-driven ROI; specifics, including any minimum subscription floor, are undisclosed.
ArisGlobal reports "34 global go-lives" in 2025 and "more than 100 new and expanded LifeSphere customers," without publishing a timeline matrix by organisation size. Third-party analysis describes LifeSphere RIM as "highly configurable… complex and expensive to implement" with "extensive Q&A/UAT for custom workflows." ArisGlobal maintains a Consulting practice. The April 2025 "Shared Success Model" introduces a "value-first engagement commitment that guarantees automation-driven ROI"; scope and inclusions are undisclosed. ArisGlobal does not address migration paths from Veeva Vault RIM, Lorenz docuBridge, or EXTEDO in public collateral. It references "simple migration" for existing LifeSphere customers moving to the relaunched 2024 platform.
PharmaSpotter assessment from published vendor and third-party sources. No user reviews are on file for this product.
Strengths
Analysts most often credit LifeSphere RIM's configurability and integration with the pharmacovigilance suite. Third-party commentary notes "LifeSphere RIM is praised for its powerful configurability and advanced features. It is one of the few solutions with built-in E2B safety integration." ArisGlobal cites a 50%+ efficiency-gain claim following the 2024 relaunch, a vendor figure not independently validated. Gens & Associates named LifeSphere RIM Market Leader in IDMP Readiness, an IDMP-specific endorsement.
Limitations & Open Questions
Practitioner-aggregated commentary flags configuration burden and historical lag in publishing capability: "Highly configurable means it can be complex and expensive to implement. Clients must plan extensive Q&A/UAT for custom workflows." Smaller biotechs may be deterred by the IT and regulatory resources required. Third-party review volume across G2, Capterra, and TrustRadius is thin.
Help the community
Share your experience with ArisGlobal LifeSphere RIM anonymously. Your insights help pharmaceutical professionals make better software decisions.
Contribute Anonymous FeedbackPublicly disclosed pharmaceutical and biotech organizations
Jump to section